| Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu L Zhang, YT Tai, M Ho, L Xing, D Chauhan, A Gang, L Qiu, KC Anderson Blood cancer journal 7 (3), e547-e547, 2017 | 84 | 2017 |
| APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications YT Tai, L Lin, L Xing, SF Cho, T Yu, C Acharya, K Wen, PA Hsieh, J Dulos, ... Leukemia 33 (2), 426-438, 2019 | 79 | 2019 |
| A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity J Liu, T Song, W Zhou, L Xing, S Wang, M Ho, Z Peng, YT Tai, ... Leukemia 33 (1), 171-180, 2019 | 70 | 2019 |
| Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma L Lin, SF Cho, L Xing, K Wen, Y Li, T Yu, PA Hsieh, H Chen, M Kurtoglu, ... Leukemia 35 (3), 752-763, 2021 | 59 | 2021 |
| A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma L Xing, L Lin, T Yu, Y Li, SF Cho, J Liu, K Wen, PA Hsieh, K Kinneer, ... Leukemia 34 (8), 2150-2162, 2020 | 51 | 2020 |
| BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma SF Cho, L Lin, L Xing, Y Li, T Yu, KC Anderson, YT Tai Cancers 12 (6), 1473, 2020 | 48 | 2020 |
| The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models SF Cho, L Lin, L Xing, Y Li, K Wen, T Yu, PA Hsieh, N Munshi, J Wahl, ... Blood advances 4 (17), 4195-4207, 2020 | 47 | 2020 |
| VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo T Yu, B Chaganty, L Lin, L Xing, B Ramakrishnan, K Wen, PA Hsieh, ... Blood Cancer Journal 10 (11), 110, 2020 | 37 | 2020 |
| Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma SF Cho, L Xing, KC Anderson, YT Tai Cancers 13 (23), 6136, 2021 | 33 | 2021 |
| AMG 701 potently induces anti-multiple myeloma (MM) functions of T cells and IMiDs further enhance its efficacy to prevent MM relapse in vivo SF Cho, L Lin, L Xing, K Wen, T Yu, PA Hsieh, Y Li, NC Munshi, J Wahl, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 26 | 2019 |
| Anti-BCMA BiTE® AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment SF Cho, L Lin, L Xing, J Liu, T Yu, K Wen, P Hsieh, N Munshi, K Anderson, ... Blood 132, 592, 2018 | 25 | 2018 |
| ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment J Liu, T Hideshima, L Xing, S Wang, W Zhou, MK Samur, T Sewastianik, ... Science Advances 7 (23), eabg2697, 2021 | 20 | 2021 |
| BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression L Xing, S Wang, J Liu, T Yu, H Chen, K Wen, Y Li, L Lin, PA Hsieh, ... Clinical Cancer Research 27 (19), 5376-5388, 2021 | 19 | 2021 |
| MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple … YT Tai, L Xing, L Lin, T Yu, SF Cho, K Wen, K Kinneer, N Munshi, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e154-e155, 2019 | 16 | 2019 |
| γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation H Chen, T Yu, L Lin, L Xing, SF Cho, K Wen, K Aardalen, A Oka, J Lam, ... Blood cancer journal 12 (8), 118, 2022 | 15 | 2022 |
| AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the … SF Cho, L Lin, L Xing, K Wen, T Yu, J Wahl, K Matthes, N Munshi, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e54, 2019 | 15 | 2019 |
| Monoclonal antibody: a new treatment strategy against multiple myeloma SF Cho, L Lin, L Xing, T Yu, K Wen, KC Anderson, YT Tai Antibodies 6 (4), 18, 2017 | 14 | 2017 |
| Anti-Bcma PBD MEDI2228 combats drug resistance and synergizes with bortezomib and inhibitors to DNA damage response in multiple myeloma L Xing, L Lin, T Yu, Y Li, K Wen, SF Cho, PA Hsieh, K Kinneer, NC Munshi, ... Blood 134, 1817, 2019 | 13 | 2019 |
| CD8+ Anti-BCMA mRNA CAR T-cells effectively kill human multiple myeloma cells in vitro and in vivo L Lin, L Xing, CM Acharya, K Wen, J Liu, P Hsieh, M Kurtoglu, ... Blood 130, 3067, 2017 | 9 | 2017 |
| Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review L Xing, Q He, L Xie, H Wang, Z Li haematologica 107 (5), 1226, 2022 | 8 | 2022 |
